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Introduction: Breast cancer and acquired immunodeficiency syndrome (AIDS)
are key issues for modern medicine. The aim of the current study was to present
how cytokines, in the example of IL-6 and its polymorphism, can affect these
two conditions. 
Material and methods: Thirty-one women with benign breast tumours, 42 breast
cancer patients and 40 HIV-infected females were enrolled in the study. Serum
IL-6 levels were determined by ELISA. The IL-6 polymorphism was genotyped
by PCR-RFLP . 
Results: Serum IL-6 in patients with benign breast tumours was significantly
lower than in females with breast cancer (p = 0.017) and HIV-infected women
(p = 0.032). We did not find statistically significant differences in serum IL-6
level between females with breast cancer and HIV-infected women (p = 0.749).
Comparing the distribution of genotypes and frequency of the IL-6 (–174) C/G
polymorphism between the three study groups – breast cancer patients, patients
with benign breast tumours, and HIV-infected patients – we did not find any
statistically significant differences. 
Conclusions: IL-6 can play an important role in pathogenesis of breast cancer
and HIV infection and its level is higher than in the control group irrespective
of distribution of genotypes and frequency of the IL-6 (–174) C/G polymorphism.
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Introduction
Most research shows that breast cancer occurs less frequently in
women infected with HIV than in those not infected [1-5]. Several
hypotheses have been proposed to try to explain this tendency. It could
be caused by the direct suppressive effect the virus has on the proliferation
of breast cancer cells, or by its effect on the functioning of the immune
system.
Not all authors agree on this matter. Pathologists in India [6] have
observed that breast cancer is the most common AIDS unrelated cancer
which occurs in HIV-infected women. Furthermore, they have shown, in
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who had not been infected.
Recent data suggest that chemokines might not
only be the main protagonists in breast cancero  -
genesis but could also play an essential role in the
pathogenesis of HIV. IL-6 possibly plays an
important role, as a pro-inflammatory chemokine,
in both of these processes. The role of IL-6 in
carcinogenesis in patients with chronic viral
infection such as HIV infection is truly interesting.
Lee et al. demonstrated that HIV-1 Tat protein,
actively released from HIV-infected cells, up-
regulates expression of IL-6 and IL-8 in human
breast cancer cells by an NF-κB-dependent pathway
[7]. Moreover, IL-6 concentration is dependent on
many environmental and genetic factors, which
determine individual differences in the production
of this cytokine. One of these factors is the 
–174 C/G polymorphism, which is found in the
promoter region of the IL-6 gene. The presence of
the G/G allele is connected with higher
concentrations of IL-6 and is seen most frequently.
Other polymorphic forms such as C/C or G/C alleles
are associated with lower levels of IL-6. 
The aim of the study was to assess serum IL-6
levels and –174 G/C polymorphism in the promoter
region of the IL-6 gene in three groups of patients:
females with benign breast tumours, breast cancer
patients, and HIV-infected women. 
Material and methods
Between January and September 2007, 
31 women with benign breast disease, 42 breast
cancer patients, and 40 HIV-infected females
treated respectively in the Department and
Outpatient Department of Surgical Oncology,
Copernicus Memorial Hospital, and the Outpatient
Department of Acquired Immunodeficiencies,
Medical University of Lodz, were recruited into the
study after ethical approval from the Medical
University of Lodz. Following written informed
consent, blood samples were collected, from
surgically treated women preoperatively. All breast
disease was diagnosed by means of clinical
examination, ultrasonography, mammography, fine
needle aspiration or core biopsy and histo  -
pathological examination in those patients
operated upon. 
The mean age of women with benign breast
lesions, who formed the control group, was 36.03
years (range 19-68 years). The mean tumour
diameter was 31.3 mm (range 7-80 mm). This
cohort included 22 patients with fibroadenomas, 
4 women with mammary cysts and 5 adenolipomas.
No signs of inflammation or cancer were present.
No history of concomitant diseases was reported.
The age of breast cancer patients ranged
between 30 and 64 years (mean 37.69 years). This
cohort included 2 cases of ductal carcinoma in situ,
33 cases of invasive ductal carcinoma and 7 lobular
cancers. The mean tumour diameter was 29.57 mm
(range 4-100 mm). Twenty-two females were
oestrogen receptor (ER) positive, 18 were
progesterone receptor (PR) positive, and 10 were
HER-2 positive. In 16 subjects positive axillary lymph
nodes were present. No distant metastases were
detected. Nine cancer patients received neo  -
adjuvant chemotherapy. 
The mean age of HIV-infected women was 34.75
years (range 22-65 years). CD 4 T cell count ranged
between 34 and 2006 cells/μl (mean 438.05).
Viraemia was under 40 copies/ml in 14 subjects. 
In 26 HIV-infected patients viraemia ranged
between 52 and 222 000 copies/ml, mean 22 566.2
copies/ml. Twenty-three females out of 40 
HIV-infected individuals were treated with
antiretroviral agents. In 4 HIV-infected patients
benign breast lesions (3 lipomas and 1 benign
mammary dysplasia) were diagnosed by means of
clinical examination, ultrasonography, mammo  -
graphy and fine needle aspiration. No breast
cancers were found in this group of patients. 
Serum IL-6 levels were determined by sandwich-
type enzyme-linked immunosorbent assay 
(ELISA) according to the manufacturer's protocol:
PeliKineCompact human IL-6 ELISA kit (Sanquin
Reagents, Amsterdam, The Netherlands) for the
quantification of IL-6. The absorbance was read at
450 nm.
The IL-6 polymorphism was genotyped by
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP). Primer sequences for PCR
were as follows: 5'-TGACTTCAGCTTTACTCTTTGT-3',
5'-CTGATTGGAAACCTTATTAAG-3'. PCR was carried
out in a volume of 25 μl containing 1.5 mmol/l
MgCl2, 0.2 mmol/l of each deoxynucleotide
triphosphates, 0.2 mmol/l of each primer (Euro  -
gentec, Darmstad, Belgium) and 2.5 units of Taq
polymerase (Qiagen GmbH, Hilden, Germany). 
The DNA was amplified during 35 cycles with an
initial denaturation at 94°C for 10 min, and final 
extension at 72°C for 10 min. The cycle programme
consisted of 1 min denaturation at 94°C, 1 min 
and 35 s annealing at 55°C, and 1 min extension at
72°C. PCR products were digested with Sf  a NI
restriction enzyme at 37°C overnight and
electrophoresed on a 2% agarose gel. Sf  a NI
restriction fragment-length polymorphism (RFLP)
was detected by ethidium bromide staining. PCR
was used to detect the IL-6 Sf  a NI RFLP . The
identified genotypes were named according to the
presence or absence of the enzyme restriction sites,
so Sf  a NI G/G, G/C, and C/C are homozygous for
the presence of the site (140/58 bp), heterozygous
for the presence and absence of the site
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of the site (198 bp), respectively.
Probability (p) value < 0.05 was considered
statistically significant. The t-test (for normal
distribution) or Mann-Whitney test (for non-normal
distribution) was used to compare each variable
between two groups. An ANOVA test was used to
identify variables showing significant differences
between more than two groups; Scheffe's test was
then used to test the significance of difference in
each identified variable between any two groups.
Analyses were performed using STATISTICA 6.0
(StatSoft, Tulsa, OK).
Results
The mean age of women with benign breast
lesions was 37.03 years (range 19-68 years). The mean
tumour diameter was 31.3 mm (range 7-80 mm). 
The age of breast cancer patients ranged between
30 and 64 years (mean 38.69 years). This cohort
included 2 cases of ductal carcinoma in situ, 
33 cases of invasive ductal carcinoma, and 
7 patients with lobular cancer. The mean tumour
diameter was 29.57 mm (range 4-100 mm). Twenty-
two females were ER positive, 18 were PR positive,
and 10 were HER-2 positive. Nine cancer patients
received neoadjuvant chemotherapy. The mean age
of HIV-infected women was 34.75 years (range 22-
65 years). CD 4 count ranged between 34 and 2006
cells/μl (mean 438.05). Viraemia was below 
40 copies/ml in 14 subjects. In 26 HIV-infected
patients, viraemia ranged between 52 and 222 000
copies/ml (mean 22 566.2 copies/ml). Twenty-three
females of 40 HIV-infected individuals were treated
with antiretroviral agents. In 4 HIV-infected patients
benign breast lesions were diagnosed by means 
of clinical examination, ultrasonography, mammo  -
graphy and fine needle aspiration. No breast
cancers were found in the aforementioned group. 
In women with benign breast tumours the level
of IL-6 ranged between 0 and 110.25 pg/ml, mean
20.24 pg/ml, in breast cancer patients between 
0 and 153.44 pg/ml, mean 25.17 pg/ml, and in 
HIV-infected females between 10.09 and 216.50
pg/ml, mean 47.36 pg/ml, respectively (Table I). 
Serum IL-6 levels (in pg/ml) in the three study
groups are shown in Table I. Serum IL-6 in patients
with benign breast tumours was significantly lower
than in females with breast cancer (p = 0.017) and
HIV-infected women (p = 0.032). We did not find
statistically significant differences in serum IL-6
level between females with breast cancer and HIV-
infected women (p = 0.749). Serum IL-6 levels
depending on genotypes in patients with benign
breast tumours, breast cancer and HIV are
presented in Tables II-IV, respectively.
The frequency of G/G genotype in breast cancer
patients, HIV-infected subjects and women with
benign breast lesions was 0.54, 0.59 and 0.59,
Benign breast tumours, N = 31 Breast cancer, N = 42 HIV, N = 40
Mean 20.24 25.17 47.36
SD 17.94 21.67 61.32
SEM 3.22 3.34 9.69
Median (25%; 75%) 18.16 (12.88; 22.55) 21.73 (17.51; 25.76) 21.27 (15.17; 36.72)
Min 0.00 0.00 10.09
Max 110.25 153.44 216.50
Table I. Serum IL-6 levels (in pg/ml) in patients with benign breast tumours, breast cancer and HIV
Genotype Mean SD Min Max Median (25%; 75%) Statistical analysis
G/G 16.64 5.67 6.30 25.44 16.91 (12.39; 21.47) G/G vs. G/C p = 0.366
G/C 25.72 29.04 0.00 110.53 19.71 (13.52;23.60)
C/C – – – – –
Table II. Serum IL-6 levels (pg/ml) depending on genotypes in patients with benign breast tumours. Statistical analysis
Genotype Mean SD Min Max Median (25%; 75%) Statistical analysis
G/G 26.37 29.15 0.00 153.44 20.90 (15.87; 27.07) G/G vs. G/C p = 0.488
G/C 24.35 8.65 11.29 46.62 23.15 (18.08; 25.60)
C/C 15.86 – 15.86 15.86 15.86 (----; ----)
Table III. Serum IL-6 levels (pg/ml) depending on genotypes in breast cancer patients. Statistical analysis
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C/C genotypes are presented in Tables V-VII.
Discussion
Numerous controversies have arisen over the
role of IL 6 in breast cancer development. Some
researchers emphasize the protective role this
cytokine has on the development of this tumour.
They point out its suppressive effect on the growth
of diverse cell lines associated with breast cancer
development as well as its anti-adhesive properties
[8-10]. Moreover, this cytokine plays an essential
role in the regulation of processes associated with
the production of oestrogens, through its effect on
such enzymes as aromatase and steroid sulfatase,
also called 17β-hydroxysteroid dehydrogenase,
which may have an effect on the risk of developing
breast cancer. A raised concentration of IL 6 was
observed to be an independent, favourable
prognostic factor in the course of breast cancer 
Genotype Mean SD Min Max Median (25%; 75%) Statistical analysis
G/G 47.31 64.34 10.96 216.51 19.63 (13.74; 39.67) G/G vs. G/C p = 0.310
G/C 49.85 62.56 11.53 205.14 24.46 (18.99; 29.58)
C/C 34.76 – 34.76 34.76 34.76
Table IV. Serum IL-6 levels (pg/ml) depending on genotypes in HIV-infected patients. Statistical analysis 
Genotype Breast cancer patients (n = 41) Benign breast tumours (n = 30)a Odds Ratio 
Allele Number (Frequency)N umber (Frequency) (95% CI)
G/G 22 (0.54) 19 (0.63) 0.67 (0.25; 1.76)
G/C 18 (0.44) 11 (0.37) 1.35 (0.51; 3.55)
C/C 1 (0.02) 0 (0.00) –
G 62 (0.76) 49 (0.82) 0.69 (0.30; 1.59)
C 20 (0.24) 11 (0.18) 1.43 (0.63; 3.28)
Table V. Distribution of genotype and frequency of IL-6 (-174) G/C polymorphism in breast cancer patients and benign
breast tumours 
ap > 0.05 distribution consistent with Hardy-Weinberg equilibrium
Genotype HIV-infected patients (n = 39) Benign breast tumours (n = 30)a Odds ratio 
Allele Number (frequency)N umber (frequency) (95% CI)
G/G 23 (0.59) 19 (0.63) 0.83 (0.31; 2.21)
G/C 15 (0.38) 11 (0.37) 1.08 (0.40; 2.88)
C/C 1 (0.03) 0 (0.00) –
G 61 (0.78) 49 (0.82) 0.81 (0.34; 1.87)
C 17 (0.22) 11 (0.18) 1.24 (0.53; 2.89)
Table VI. Distribution of genotype and frequency of IL-6 (-174) G/C polymorphism in HIV-infected patients and benign
breast tumours  
ap > 0.05 distribution consistent with Hardy-Weinberg equilibrium 
Genotype Allele HIV-infected patients (n = 39) Breast cancer patients (n = 41) 
Number (frequency)N umber (frequency)
G/G 23 (0.59) 22 (0.54)
G/C 15 (0.38) 18 (0.44)
C/C 1 (0.03) 1 (0.02)
G 61 (0.78) 62 (0.76)
C 17 (0.22) 20 (0.24)
Table VII. Distribution of genotype and frequency of the IL-6 (-174) G/C polymorphism in HIV-infected patients and
breast cancer patients 
p > 0.05 distribution in HIV-infected patients consistent with distribution in breast cancer patients 
IL-6 in HIV and breast pathologies 
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researchers have found that women with breast
cancer had a higher concentration of this
interleukin in comparison with healthy women.
They also stated that these women had a worse
prognosis [13]. 
Thanks to the development of molecular
genetics, changes in single nucleotides in
polymorphic fragments of coding genes which are
responsible for the production of this interleukin
have been discovered. It has been found that the
presence of different allelic forms in these
fragments is connected with different affinities
towards transcription factors which in effect
contribute to diverse protein expression. The G/G
allele is connected with higher concentrations of
IL-6 and is seen most frequently. Other polymorphic
forms such as C/C or G/C alleles are associated with
lower levels of IL-6.
Knowing that IL-6 plays an important role in the
process of carcinogenesis, many researchers have
started to try to establish the significance of
polymorphic changes in the 174 position to
determine the risk of breast cancer development
as well as the risk of progression of this disease.
The results of many publications pertaining to this
topic are contradictory.
Hefler et al. (14) stated that the IL-6 gene G-174C
increases the risk of breast cancer development.
Other researchers, on the other hand, have not
published statistically significant results comparing
the prevalence of certain alleles in women with
breast cancer in comparison with their prevalence
in healthy women [1, 10, 12, 15-17]. DeMichele et al.
[16] believe that G-174C IL-6 polymorphism is
a better prognostic factor in patients with high risk
breast cancer. However, Iacopetta et al. [18] stated
that the occurrence of polymorphism is a prognostic
factor pointing toward a more aggressive course of
breast cancer progression. Other researchers found
there to be no connection between IL-6 gene 174
polymorphism and the clinical or histopathological
outcome of breast cancer [15, 14, 18].
In the presented research we found there to be
a statistically significantly higher level of IL-6 in the
group of patients with breast cancer compared to
the group with benign breast tumours. We did not
perform subgroup analysis of cytokine
concentrations in the breast cancer cohort in
relation to staging, due to the small numbers of
patients, but positive axillary lymph nodes were
detected in 16 out of 42 females. In our study the
G/G allele, which genetically predisposes to a higher
production of IL-6, was not significantly more
frequent in patients with breast cancer in
comparison with the group of patients with benign
breast tumours. A similar situation was seen in
patients infected with HIV. Higher concentrations,
in both the group of women with breast cancer and
that with HIV compared to the studied group of
women with benign breast lesions, were not
associated with IL-6 gene 174 polymorphism.
Therefore the observed higher concentrations of IL 6
in the groups infected with HIV and in women with
breast cancer were not associated with the genetic
determinants which we studied.
The observation made by American researchers
in which they stated that HIV-1 Tat protein increases
the potential of human cell cultures to form
metastases through the up-regulation of both IL-6
and IL-8 as well as mRNA matrix metalloproteinase
MMP-9 [7] seems interesting. However, in the group
of HIV patients which we studied, we did not have
any cases of breast cancer; therefore it is hard to
relate to this observation. 
IL-6 can play an important role in the
pathogenesis of breast cancer and HIV infection,
and its level is higher than in the control group
irrespective of the distribution of genotypes and
frequency of the IL-6 (–174) C/G polymorphism.
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